The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial
File version
Version of Record (VoR)
Author(s)
Riedl, Regina
Geetha, Duvuru
Szpirt, Wladimir M
Hawley, Carmel
Uchida, Lisa
Wallace, Zachary S
Walters, Giles
Muso, Eri
Tesar, Vladimir
Pusey, Charles D
Little, Mark A
Merkel, Peter A
Walsh, Michael
Jayne, David RW
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
Therapeutic plasma exchange (PLEX) is an adjunctive treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and kidney involvement. Little is known about the effect of PLEX on early changes in kidney function. This post-hoc analysis of the PEXIVAS trial investigated the effects of PLEX on changes in kidney function within 12 months. PEXIVAS was a randomized controlled trial recruiting 691 patients with ANCA-associated glomerulonephritis, of whom 349 underwent PLEX and 342 received no-PLEX. The primary outcomes of this post hoc study of PEXIVAS were change in estimated glomerular filtration rate (eGFR) from baseline and recovery of kidney function (defined as eGFR increase of 15ml/min/1.73m2 or more).
Journal Title
Kidney International
Conference Title
Book Title
Edition
Volume
107
Issue
3
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2024, International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Item Access Status
Note
Access the data
Related item(s)
Subject
Persistent link to this record
Citation
Odler, B; Riedl, R; Geetha, D; Szpirt, WM; Hawley, C; Uchida, L; Wallace, ZS; Walters, G; Muso, E; Tesar, V; Pusey, CD; Little, MA; Merkel, PA; Walsh, M; Jayne, DRW; Kronbichler, A, The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial, Kidney International, 2025, 107 (3), pp. 558-567